Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?

Minerva Anestesiologica

Volumn 82, Issue 9, 2016, Pages 957-965

  McDonald, Craig ^a   Cotta, Menino O Cotta ^a,b   Little, Peter J ^b   McWhinney, Brett ^c   Ungerer, Jacobus P J ^c   Lipman, Jeffrey ^a,b   Robertserts, Jason A ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Pathology Queensland ^*  (Australia)

Author keywords

Beta Lactams; Critical illness; Drug monitoring; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BETA LACTAM; BILIRUBIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ADULT; ARTICLE; BACTERIUM CULTURE; CHOLESTASIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL MORTALITY; HUMAN; INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; LICENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEIZURE; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CRITICAL ILLNESS; TOXIC HEPATITIS;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLESTASIS; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SEIZURES; THIENAMYCINS; THROMBOCYTOPENIA;

EID: 84990895391     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011;140:1223-31.
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
3. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010;38:1773-85.
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
5. Wong G, Sime F, Lipman J, Roberts J. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis 2014;14:288.
6. Taccone F, Laterre P, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010;14:R126.
7. Lorenzen J, Broll M, Kaever V, Burhenne H, Hafer C, Clajus C, et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012;7:385-90.
8. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012;142:30-9.
9. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51; quiz 859.
10. Ulldemolins M, Roberts J, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011;139:1210-20.
11. Roberts J, Ulldemolins M, Roberts M, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332-9.
12. Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014;69:1416-23.
13. ® (meropenem) for injection: product information; [Internet]. Available from: http://www.azpicentral.com/merrem/merremiv.pdf [cited 2016, Jul. 6].
14. Pfizer Pharmaceuticals. Tazocin EF (piperacillin/tazobactam) for injection: product information; [Internet]. Available from: http://secure.healthlinks.net.au/content/pf/retriever.cfm?product=pfptazev10712 [cited 2016, Jul. 6].
15. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MIC s and zone diameters. Version 50; 2015 [Internet]. Available at: http://www.eucast.org [cited 2016, Jul. 06].
16. McWhinney B, Wallis S, Hillister T, Roberts J, Lipman J, Ungerer J. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr 2010;878:2039-43.
17. Briscoe S, McWhinney B, Lipman J, Roberts J, Ungerer J. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr 2012;907:178-84.
18. Velayudham L, Farrell G. Drug-induced cholestasis. Expert Opin Drug Saf 2003;2:287-304.
19. Aithal G, Watkins P, Andrade R, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806-15.
20. Lagace-Wiens P, Rubinstein E. Adverse reactions to β-lactam antimicrobials. Expert Opin Drug Saf 2012;11:381-99.
21. Scheetz MH, Mckoy JM, Parada JP, Djulbegovic B, Raisch DW, Yarnold PR, et al. Systematic Review of Piperacillin-Induced Neutropenia. Drug Saf 2007;30:295-306.
22. Cotta MO, Gowen B, Truloff N, Bursle E, McWhinney B, Ungerer JP, et al. Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring. Infect Dis 2015;47:739-42.
23. Di Giantomasso D, May C, Bellomo R. Vital organ blood flow during hyperdynamic sepsis. Chest 2003;124:1053-9.
24. Samtani M, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010;54:2360-4.
25. Valenza G, Seifert H, Decker-Burgard S, Laeuffer J, Morrissey I, Mutters R. Comparative Activity of Carbapenem Testing (CO MPACT) study in Germany. Int J Antimicrob Agents 2012;39:255-8.
26. Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail 1998;20:809-19.
27. Owens RC. An overview of harms associated with betalactam antimicrobials: where do the carbapenems fit in? Crit Care 2008;12 Suppl 4:S3.
28. Granowitz E V., Brown RB. Antibiotic Adverse Reactions and Drug Interactions. Crit Care Clin 2008;24:421-42.
29. Grill M, Maganti R. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol 2011;72:381-93.
30. Beumier M, Casu G, Hites M, Wolff F, Cotton F, Vincent JL, et al. Elevated β-lactam concentrations associated with neurological deterioration in IC U septic patients. Minerva Anestesiol 2015;81:497-506.
31. Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
32. Garcia-Cortes M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-89.
33. Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Ann Pharmacother 2005;39:1823-7.
34. Kwon J, Lee J, Huh W, Peck KR, Kim YG, Kim DJ, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010;35:473-77.